Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Marovac, J
   Investigation and development of new medications: from the molecule to drug
   REVISTA MEDICA DE CHILE
   
   J. Marovac, "Investigation and development of new medications: from the molecule to drug", REV MED CHI, 129(1), 2001, pp. 99-106
2. Wieringa, NF; Vos, R; Van der Werf, GT; Van der Veen, WJ; De Graeff, PA
   Co-morbidity of 'clinical trial' versus 'real-world' patients using cardiovascular drugs
   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
   
   N.F. Wieringa et al., "Co-morbidity of 'clinical trial' versus 'real-world' patients using cardiovascular drugs", PHARMA D S, 9(7), 2000, pp. 569-579
3. Coleman, WP; Benzel, E; Cahill, DW; Ducker, T; Geisler, F; Green, B; Gropper, MR; Goffin, J; Madsen, PW; Maiman, DJ; Ondra, SL; Rosner, M; Sasso, RC; Trost, GR; Zeidman, S
   A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury
   JOURNAL OF SPINAL DISORDERS
   
   W.P. Coleman et al., "A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury", J SPINAL D, 13(3), 2000, pp. 185-199
4. Wieringa, NF; Vos, R; van der Werf, GT; de Graeff, PA
   Inclusion of patients with comorbidity and comedication in premarketing trials of cardiovascular drugs
   DRUG DEVELOPMENT RESEARCH
   
   N.F. Wieringa et al., "Inclusion of patients with comorbidity and comedication in premarketing trials of cardiovascular drugs", DRUG DEV R, 51(3), 2000, pp. 159-168
5. Chalumeau, M; Treluyer, JM; Salanave, B; Assathiany, R; Cheron, G; Crocheton, N; Rougeron, C; Mares, M; Breart, G; Pons, G
   Off label and unlicensed drug use among French office based paediatricians
   ARCHIVES OF DISEASE IN CHILDHOOD
   
   M. Chalumeau et al., "Off label and unlicensed drug use among French office based paediatricians", ARCH DIS CH, 83(6), 2000, pp. 502-505
6. Kanba, S
   Disparities in drug development: the Japanese paradox
   JOURNAL OF PSYCHIATRY & NEUROSCIENCE
   
   S. Kanba, "Disparities in drug development: the Japanese paradox", J PSYCH NEU, 24(1), 1999, pp. 13-14
7. Henry, V
   Off-label prescribing - Legal implications
   JOURNAL OF LEGAL MEDICINE
   
   V. Henry, "Off-label prescribing - Legal implications", J LEG MED, 20(3), 1999, pp. 365-383
8. Lambert, BL; Lin, SJ; Chang, KY; Gandhi, SK
   Similarity as a risk factor in drug-name confusion errors - The look-alike(orthographic) and sound-alike (phonetic) model
   MEDICAL CARE
   
   B.L. Lambert et al., "Similarity as a risk factor in drug-name confusion errors - The look-alike(orthographic) and sound-alike (phonetic) model", MED CARE, 37(12), 1999, pp. 1214-1225
9. LACHAUX B; GRISONCURINIER J; LACHAUX A
   EXPERIMENTATION OF DRUGS IN CHILDREN - ET HICAL AND LEGAL ISSUES
   Archives de pediatrie
   
   B. Lachaux et al., "EXPERIMENTATION OF DRUGS IN CHILDREN - ET HICAL AND LEGAL ISSUES", Archives de pediatrie, 5(4), 1998, pp. 425-431
10. Herry, F
    The freedom of prescription for the practitioner face to the requirements of the AMM, the medical references and the socio-economical compulsions
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE
    
    F. Herry, "The freedom of prescription for the practitioner face to the requirements of the AMM, the medical references and the socio-economical compulsions", B ACA N MED, 182(7), 1998, pp. 1395-1406
11. HERZ SE
    DONT TEST, DO SELL - LEGAL IMPLICATIONS OF INCLUSION AND EXCLUSION OFWOMEN IN CLINICAL DRUG TRIALS
    Epilepsia
    
    S.E. Herz, "DONT TEST, DO SELL - LEGAL IMPLICATIONS OF INCLUSION AND EXCLUSION OFWOMEN IN CLINICAL DRUG TRIALS", Epilepsia, 38, 1997, pp. 42-49
12. BIALER M; JOHANNESSEN SI; KUPFERBERG HJ; LEVY RH; LOISEAU P; PERUCCA E
    PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT CONFERENCE
    Epilepsy research
    
    M. Bialer et al., "PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT CONFERENCE", Epilepsy research, 25(3), 1996, pp. 299-319
13. STABLES JP; BIALER M; JOHANNESSEN SI; KUPFERBERG HJ; LEVY RH; LOISEAU P; PERUCCA E
    PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS A SUMMARY OF THE 2ND EILAT-CONFERENCE
    Epilepsy research
    
    J.P. Stables et al., "PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS A SUMMARY OF THE 2ND EILAT-CONFERENCE", Epilepsy research, 22(3), 1995, pp. 235-246
14. WRIGHT C
    MEDICATIONS DEVELOPMENT FOR ALCOHOL-USE DISORDERS
    Psychopharmacology bulletin
    
    C. Wright, "MEDICATIONS DEVELOPMENT FOR ALCOHOL-USE DISORDERS", Psychopharmacology bulletin, 31(4), 1995, pp. 681-686
15. ROBINSON DS
    A PHARMACEUTICAL-INDUSTRY PERSPECTIVE ON DRUG LABELING
    Psychopharmacology bulletin
    
    D.S. Robinson, "A PHARMACEUTICAL-INDUSTRY PERSPECTIVE ON DRUG LABELING", Psychopharmacology bulletin, 30(1), 1994, pp. 23-25
16. TERRY MK
    REGULATORY PROCESS FOR DRUGS USED BY THE POULTRY-INDUSTRY
    Poultry science
    
    M.K. Terry, "REGULATORY PROCESS FOR DRUGS USED BY THE POULTRY-INDUSTRY", Poultry science, 73(9), 1994, pp. 1423-1428
17. STOLLEY PD
    THE HAZARDS OF MISGUIDED COMPASSION
    Annals of internal medicine
    
    P.D. Stolley, "THE HAZARDS OF MISGUIDED COMPASSION", Annals of internal medicine, 118(10), 1993, pp. 822-823